Reuters logo
4 个月前
BRIEF-Immunomedics says sacituzumab govitecan active in patients with metastatic small-cell lung
2017年4月5日 / 上午11点19分 / 4 个月前

BRIEF-Immunomedics says sacituzumab govitecan active in patients with metastatic small-cell lung

1 分钟阅读

April 5 (Reuters) - Immunomedics Inc-

* Immunomedics reports sacituzumab govitecan (immu-132) is active in patients with metastatic small-cell lung cancer who are sensitive or resistant to first-line chemotherapy

* Immunomedics Inc - sixty percent of patients showed tumor shrinkage from baseline measurements using computed tomography in phase 2 study

* Immunomedics Inc - on an intention-to-treat basis orr was 14% median response duration was 5.7 months in study

* Immunomedics - data shows there was no statistical difference in orr, pfs or os between patients who were chemosensitive or chemoresistant to first-line chemo Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below